NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Poop pills may restore cancer drug power in lung patients
Disease control Recruiting nowThis study tests whether taking a special fecal transplant (MaaT033) alongside an immunotherapy drug (cemiplimab) can help overcome resistance caused by prior antibiotic use in people with advanced non-small cell lung cancer. About 162 participants will be randomly assigned to re…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New combo shields bone marrow in tough lung cancer cases
Disease control Recruiting nowThis study tests whether giving a bone marrow-protecting drug (trilaciclib) before chemotherapy (sacituzumab tirumotecan) can reduce serious side effects like low white blood cell counts in people with advanced EGFR-mutant lung cancer that no longer responds to standard targeted …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated May 16, 2026 22:33 UTC
-
New hope for lung cancer: targeted pill takes on tough mutations
Disease control Recruiting nowThis study tests an experimental drug, BH-30643, in people with advanced non-small cell lung cancer that has certain changes in the EGFR or HER2 genes. The goal is to find a safe dose and see if the drug can shrink tumors. About 266 adults who have already tried standard treatmen…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
New combo shot aims to reboot immune attack on tough lung cancers
Disease control Recruiting nowThis study tests a new drug, QL1706, which blocks two immune checkpoints (PD-1 and CTLA-4) at once, combined with standard chemotherapy for people with advanced non-small cell lung cancer that no longer responds to initial immunotherapy. About 96 adults whose tumors lack certain …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
New hope for hard-to-treat cancers? drug combo trial begins
Disease control Recruiting nowThis study tests a new drug called ODM-212 combined with other anti-cancer treatments in people with advanced solid tumors, including mesothelioma, pancreatic cancer, and non-small cell lung cancer. The trial has two parts: first finding a safe dose, then checking how well it wor…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New triple therapy offers hope for advanced lung cancer patients who failed first treatment
Disease control Recruiting nowThis study tests a combination of microwave ablation (a heat-based tumor destruction technique) plus two drugs (tislelizumab and docetaxel) in 20 adults with advanced non-small cell lung cancer that worsened after initial immunotherapy and chemotherapy. The goal is to see if this…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 16, 2026 22:29 UTC
-
New drug cocktail shows promise for tough cancers
Disease control Recruiting nowThis study tests a new drug called TCC1727 combined with other cancer treatments (benmelstobart, olaparib, or topotecan) for people with advanced solid tumors that have stopped responding to standard therapy. The goal is to find the safest dose and see if the combination can shri…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New pill takes on chemo for rare lung cancer mutations
Disease control Recruiting nowThis study tests a daily pill called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR gene changes (PACC or L861Q). About 300 participants will be randomly assigned to either the pill or chemo. The goal is to se…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New targeted drug ALX2004 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called ALX2004 in people with advanced or metastatic solid tumors (lung, head and neck, colorectal, esophageal) that have not responded to standard treatments. ALX2004 is an antibody drug conjugate designed to deliver chemotherapy directly …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for drug-resistant lung cancer: targeted radiation plus four-drug combo enters trial
Disease control Recruiting nowThis study tests whether adding precise radiation to a four-drug combination can help people with advanced EGFR-mutant lung cancer whose first treatment stopped working. About 53 adults will receive the drugs (sintilimab, bevacizumab, platinum, pemetrexed) plus personalized radia…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New pill hopes to shrink lung tumors in patients who failed other treatments
Disease control Recruiting nowThis early-stage study tests an experimental pill (HJ-004-02) in 36 adults with advanced non-squamous non-small cell lung cancer that has a specific EGFR gene change. Participants take the pill daily in 28-day cycles. The main goals are to check safety and find the right dose, wh…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Tongji University • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ADU-1805, alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. About 130 p…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Sairopa B.V. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New hope for Hard-to-Treat lung cancer: targeted pill takes on chemo
Disease control Recruiting nowThis study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called CAR-T cells, which are immune cells engineered to target a protein called CEA found on certain cancer cells. The study includes up to 48 adults with advanced non-small cell lung cancer or breast cancer that has not responded to …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New dosing strategy aims to tackle lung cancer brain spread
Disease control Recruiting nowThis study is for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain (leptomeningeal metastasis). It tests whether taking a higher dose of the drug furmonertinib every other day works better and is safe compared to t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
AI and better scans could speed up lung cancer radiation treatment
Knowledge-focused Recruiting nowThis study looks at whether new AI tools and improved CT scans can make adaptive radiotherapy faster and easier for people with advanced lung cancer. About 30 patients will help researchers measure how long each step takes and check if the new method is as accurate as the standar…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated May 16, 2026 22:32 UTC
-
Lung cancer genes linked to blood clot danger in new study
Knowledge-focused Recruiting nowThis study looks at how certain gene changes in advanced lung cancer patients might increase the risk of dangerous blood clots. Researchers will follow 500 patients for 6 months, measuring blood markers and tracking clot events. The goal is to learn if genetic profiles can help p…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: University Of Perugia • Aim: Knowledge-focused
Last updated May 11, 2026 20:49 UTC
-
Researchers revisit old trial data to see who benefits most from immunotherapy
Knowledge-focused Recruiting nowThis study is collecting long-term survival information from 109 people with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand the lasting benefits of this immu…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated May 04, 2026 16:30 UTC
-
Italian study seeks to uncover hidden HER2 mutations in lung cancer
Knowledge-focused Recruiting nowThis study is observing people with advanced non-small cell lung cancer (NSCLC) in Italy to learn how often HER2 mutations occur and how doctors currently treat them. About 50 participants will be followed for one year. The goal is to gather real-world information, not to test a …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated May 04, 2026 16:20 UTC